DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV: an Open-label Randomized Clinical Trial
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 554
- 试验地点
- 33
- 主要终点
- Proportion of patients with plasma HIV-1 RNA ≥50 copies/mL
研究概览
简要总结
The hypothesize that DTG/3TC will be non-inferior to BIC/FTC/TAF with a 4% margin in virologically suppressed HIV-infected patients. The study will allow claiming for Superiority. Assuming that both DTG and BIC may lead to similar weight gains (approximately 1 kg after 48 weeks) in virologically suppressed HIV-infected patients and that TAF may induce a further weight gain (approximately 1 kg after 48 weeks), also hypothesize that switching to BIC/FTC/TAF may lead to greater weight gain than switching to DTG/3TC over 48 weeks.
This trial is a Phase IV, open-label, randomized multicentre clinical trial evaluating the efficacy of DTG/3TC versus BIC/FTC/TAF for the maintenance of virological suppression in HIV patients.
详细描述
Participants will be randomly assigned in a 1:1 ratio to receive DTG/3TC or BIC/FTC/TAF. Randomization will be stratified by sex and TAF use at baseline. At least 33% of the patients included will be women.
The investigatora will also endeavour to recruit as many non-Caucasian participants as possible.
Patients with TAF-containing regimens at baseline will be limited to 25% or less of the total number of participants. Three sub-studies will be performed: Omics sub-study ; Senescence sub-study; Fat biopsies sub-study.
Omics sub-study: Assess the mechanistic pathways involved on weight changes associated with switching to BIC/FTC/TAF vs. DTG/3TC.
Senescence sub-study: Assess the potential effects on the telomere length, epigenetic age and oxidative stress markers of switching to BIC/FTC/TAF vs. DTG/3TC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Understanding the study information provided and being capable of giving written informed consent.
- •Confirmed HIV infection.
- •≥18 years of age on the day of screening.
- •HIV RNA <50 copies/mL for at least 24 weeks before screening.
- •Receiving any regimen for HIV containing more than 1 pill a day or any single tablet regimen containing at least one of the following: cobicistat-boosting, efavirenz, or tenofovir disoproxyl fumarate, for at least 24 weeks before screeningPatients with TAF are expected from cobiscitat-boosting single tablet regimens containing darunavir or elvitegravir and from more-than-1-pill-a-day regimens containing TAF/FTC; their participation will be limited to ≤25%. Patients will be stratified according to the presence or not of TAF in their regimens.
- •No evidence of previous viral failure.
- •No known or suspected resistance to study drugs.
- •Females of childbearing potential, must be using highly effective methods of contraception from study inclusion and for at least 4 weeks after last study visit; all female volunteers must be willing to undergo urine pregnancy testing at the time points specified in the schedules of events.
- •Clinical stability: Participants who are healthy (other than HIV infection) as determined by the Investigator or medically qualified designee based on a medical evaluation including medical history, laboratory tests, and cardiac monitoring.
排除标准
- •Is pregnant or lactating at the screening visit or at any time during the study or is planning on becoming pregnant over the duration of the study.
- •Evidence of Hepatitis B virus infection based on at least one positive result of testing at Screening for Hepatitis B surface antigen (HBsAg) and Hepatitis B core antibody (anti- HBc).
- •Previous or current therapy with dolutegravir or bictegravir.
- •History of allergy to study drugs or their components.
- •Liver disease as defined by ALT >= 5x ULN or ALT >=3xULN and Bili >=1.5xULN (with >35% direct bilirubin).
- •Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormalities (apart from hyperbilirubinemia or jaundice due to Gilbert's syndrome or asymptomatic gallstones);
- •Subjects with severe hepatic impairment (Class C) as determined by Child-Pugh classification and/or anticipated need for Hep C treatment.
- •Kidney disease as defined by CKD-EPI <50ml/min.
- •Any recently (<=6 months) diagnosed clinical condition or recently (<=6 months) initiated concomitant therapy (see Section 6.5) that may primarily affect weight or body composition. E.g., including but not limited to endocrine disorders, osteoporosis or medications to treat these clinical conditions, with the exception of controlled diabetes mellitus.
研究组 & 干预措施
Dovato arm
DTG/3TC
干预措施: Dolutegravir/Lamivudine as a single pill (Drug)
Biktarvy arm
BIC/FTC/TAF
干预措施: Bictegravir/Emtricitabine/Tenofovir alfenamide as a single pill. (Drug)
结局指标
主要结局
Proportion of patients with plasma HIV-1 RNA ≥50 copies/mL
时间窗: Week 48
次要结局
- Proportion of patients with plasma HIV-1 RNA <50 copies/mL(Week 48 and week 96)
- Proportion of patients with plasma HIV-1 RNA ≥50 copies/mL(week 96)
- Absolute weight(Basal, week 48 y week 96)
- BMI change(Basal, week 48 y week 96)
- Proportion of patients with weight change >5%(Basal, week 48 y week 96)
- Absolute values in CD4+ cells count(Basal, week 48 y week 96)
- Changes in CD4+ cells count(Basal, week 48 y week 96)
- Absolute values CD4:CD8 ratio(Basal, week 48 y week 96)
- Changes CD4:CD8 ratio(Basal, week 48 y week 96)
- Change in total and regional (trunk and extremities) fat by DXA(Basal, week 48 y week 96)
- Change in total and regional (trunk and extremities) fat-free mass by DXA(Basal, week 48 y week 96)
- Change in lumbar and hip bone mineral density (BMD) by DXA(Basal, week 48 y week 96)
- Change trabecular bone score (TBS) by DXA(Basal, week 48 y week 96)
- Change in subcutaneous and visceral fat (CT)(Basal, week 48 y week 96)
- Change in fasting glucose cholesterol, triglycerides), and FIB-4 score(Basal, week 48 y week 96)
- Change insulin cholesterol, triglycerides), and FIB-4 score(Basal, week 48 y week 96)
- Change in HOMA-IR cholesterol, triglycerides), and FIB-4 score(Basal, week 48 y week 96)
- Change in HbA1c cholesterol, triglycerides), and FIB-4 score(Basal, week 48 y week 96)
- Change in plasma lipids (total, HDL, and LDL) cholesterol, triglycerides), and FIB-4 score(Basal, week 48 y week 96)
- Changes in estimated glomerular filtration rate (CKD-EPI)(Basal, week 48 y week 96)
- Change in anxiety and depression (HAD) quality of life (HIV Symptom Index questionnaire / Symptom Distress Module (HIV-SI/SDM(From basal, until week 96 , in each visit)
- Change in sleep quality (Pittsburg Sleep Quality Index)(From basal, until week 96 , in each visit)
- Change in quality of life (HIV Symptom Index questionnaire / Symptom Distress Module (HIV-SI/SDM)(From basal, until week 96 , in each visit)
- Incidence of adverse events leading to treatment discontinuation.(From basal, until week 96 , in each visit)
- Changes in urinary protein/creatinine(Basal, week 48 y week 96)
- Change in blood pressure(Basal, week 48 y week 96)
- Incidence and severity of adverse events (clinical and laboratory)(From basal, until week 96 , in each visit)
- Incidence of genotypic resistance mutations in participants with virological failure(Week 48 and week 96)